03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
20:07 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample, cell culture and mouse studies suggest activating AMPK could help treat pulmonary fibrosis. In lung tissue samples from idiopathic pulmonary fibrosis (IPF) patients, fibroblast levels of activated AMPK were lower than...
19:19 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting AMPK could help treat glioma. In tumor samples from glioblastoma and low-grade glioma patients, levels of activated AMPK were higher than in brain tissue...
22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
20:53 , Oct 5, 2017 |  BC Innovations  |  Translation in Brief

AMPK addendum

A Science paper form Merck & Co. Inc. (NYSE:MRK) suggests that while AMP-activated protein kinase (AMPK) agonists can reduce blood sugar levels and treat diabetes models, they also cause cardiac defects, casting doubt on AMPK...
20:00 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest AMPK activators could help treat non-alcoholic fatty liver disease (NAFLD). In mice, liver-specific expression of an overactive human mutant AMPK decreased glucose production and fatty acid synthesis compared with no...
00:16 , Apr 7, 2017 |  BC Innovations  |  Targets & Mechanisms

Mastering mTOR

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...
19:00 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Myotonic dystrophy type 1 (DM1) Patient sample and mouse studies suggest activating AMPK or inhibiting mTORC1 could help treat DM1. In muscle tissue samples from patients and a genetic mouse model of DM1, levels of...
01:46 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; skin cancer Mouse studies suggest combining anti-PD-L1 therapies and promoters of reactive oxygen species (ROS) production or agonists of the mTOR or AMPK signaling pathways could help treat colorectal and skin cancers. In...
21:19 , Nov 10, 2016 |  BC Innovations  |  Translation in Brief

Cutting the cancer fat

Nimbus Therapeutics LLC has shown one of its computationally designed acetyl-Coenzyme A carboxylase (ACC; ACAC) inhibitors, dubbed ND-646, can block the fatty acid synthesis that fuels growth of lung tumors, and has developed a biomarker...